Levetiracetam Articles
UCB heading for growth phase as new products drive 2012 sales
28 February 2013
Mylan debuts innovative version of levetiracetam
19 January 2012
Otsuka Pharma and UCB re-focus collaboration
16 January 2012
UCB agrees $34.4 million settlement for off-label promotion of Keppra in USA; Novo to pay $25 million over NovoSeven
13 June 2011
Belgium’s UCB posts disappointing 2009 results, but projects better future based on newer drugs
3 March 2010
UCB revenue falls on drop in US sales
1 May 2009
UCB absorbs Zyrtec patent expiry, but 2008 profit still down 74% on restructuring charges
9 March 2009
Taro's generic levetiracetam cleared by US FDA
16 February 2009
Cypress gains FDA approval for generic Keppra
26 January 2009
Roxane's generic Keppra cleared in USA
26 January 2009
Anti-epileptics to get suicide warnings in USA
22 December 2008
Mylan gets final OK for Keppra generic
10 November 2008
UCB drops 12% on Neupro batches recall
31 March 2008
UCB's 2007 net profit down 59% on M&A
10 March 2008
UCB raises guidance for 2008 above consensus
24 December 2007
UCB settles US Keppra patent suit
15 October 2007
UCB's 1st-half profits fall 39% on Schwarz buy
6 August 2007
Cimzia key drug in UCB 2007 R&D update
7 May 2007
UCB's Keppra effective in infant seizure study
30 April 2007
Keppra gets FDA OK as PGCT seizure therapy
26 March 2007
Keppra "non-inferior" to CR carbamazepine
5 March 2007
New EU epilepsy approval for UCB
22 January 2007
UCB's Keppra cleared in USA as adjunct therapy
4 September 2006
UCB's Keppra available to new epilepsy patients
28 August 2006
UCB 1st-half results ahead of forecasts
7 August 2006
EC clears UCB's Keppra as adjunctive JME drug
22 May 2006
UCB's Keppra gets expanded indication in EU
1 May 2006
UCB sees 2005 income grow to 270M euros
20 March 2006
CMPH gives nod to UCB's Keppa for EU appro
13 February 2006
UCB projects income of 260 M euros for 2005
19 December 2005
UCB 1st-half net profits leap 232%
8 August 2005
EMEA recommends UCB's Keppra for pediatric use
8 August 2005
Orphan status for UCB's brivaracetam in EU?
1 August 2005
FDA OKs Keppra for children with epilepsy
4 July 2005
Stock Commentary - Europe
4 July 2005
UCB given priority review for Keppra by FDA
28 February 2005
Celltech boosts UCB 2004 results
14 February 2005
UCB submits pediatric and IV Keppra filings
10 January 2005
UCB hikes R&D budget nearly 60%
10 January 2005
UCB opens new $40M Keppra facility
20 December 2004
UCB Pharma introduces Keppra pregnancy registry
13 December 2004
UCB's Keppra effective in treating partial seizures in children; filing expected year-end
13 December 2004
UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care
8 November 2004
UK NICE guidance on insomnia drugs
10 May 2004
Keppra sales data and Pfizer rumors boost UCB
19 April 2004
Keppra growth and a "buy" seen by UCB
29 March 2004
UK NICE backs newer antiepileptics
29 March 2004
Dr Reddy's files for US generic levetiracetam
29 March 2004
UCB's Keppra forges ahead
9 February 2004
UCB Pharma's Keppra effective in controlling seizures in the elderly
22 December 2003
Keppra effective in brain tumor patients
8 December 2003
Keppra effective in refractory epilepsy
20 October 2003
UCB Pharma debuts Keppra in France
29 September 2003
New data for UCB Pharma's Keppra
15 September 2003
UCB Pharma's Keppra solution gets FDA OK
28 July 2003
UCB's Keppra gives pain relief in MS
31 March 2003
Canada approves UCB's Keppra
24 March 2003
Zyrtec continues to drive UCB pharma
17 February 2003
UCB raises 2003 R&D investment 17%
13 January 2003
Profits on the increase at Belgium's UCB Group
15 April 2002
Zyrtec driving sales and earnings at UCB
18 February 2002
UCB to post 20% profit growth in 2001
12 December 2001
Update: UCB 1st-half pharma turnover leaps 31%
31 July 2001
UCB 1st-half pharma sales leap 31%
30 July 2001
UCB 1st-half pharma sales leap 31%
27 July 2001
Good start to 2001 for UCB pharma
15 June 2001
UCB profits up 23% in 2000
11 April 2001
UCB 2000 turnover increases 20%
20 February 2001
Healthy harvest of New Chemical Entities in 2000
2 January 2001
UCB's Keppra launch plans following European Union approval
19 October 2000
UCB's Keppra OKed in Europe for epilepsy
5 October 2000
UCB reports 27% growth in pretax profit
31 July 2000
UCB's Keppra backed by CPMP
31 July 2000
UCB gains Swiss approval for Keppra
12 April 2000
Good second-half 1999 boosts UCB earnings
3 April 2000
UCB pharma sales up 19% for 1999
9 February 2000
UCB expecting 20% earnings rise for 1999
15 December 1999
UCB forecasts $200m Keppra sales
9 December 1999
First approval for UCB Pharma's Keppra
2 December 1999
UCB Pharma's levetiracetam, Phase III data show efficacy in epilepsy
14 September 1999
Profits climb 30% at Belgium's UCB
9 February 1999
Belgium's UCB Reviews Research
15 June 1998
EARNINGS GROWTH EXPANSION SEEN FOR UCB
31 May 1993
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
